{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T23:40:10Z","timestamp":1738798810800,"version":"3.37.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81971991"],"award-info":[{"award-number":["81971991"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Zhejiang\u00a0Provincial\u00a0Natural\u00a0Science\u00a0Foundation\u00a0of\u00a0China","award":["Y23H080003"],"award-info":[{"award-number":["Y23H080003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>5-Azacytidine (AZA) combined with the BCL2 inhibitor Venetoclax (VEN) is the standard treatment for elderly acute myeloid leukemia (AML) patients or those who are unfit for intensive chemotherapy (elderly or unfit AML). However, an effective and rapid predictive biomarker to predict treatment outcome remains elusive.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>miR-182 promoter methylation was measured in 94 AZA\u2009+\u2009VEN-treated elderly or unfit AML patients and 20 normal controls (NCs) samples. To determine whether miR-182 promoter methylation is a predictive marker of clinical outcomes in AZA\u2009+\u2009VEN-treated AML patients in a real-world setting, we analyzed and compared the complete remission (CR)\/CR with incomplete hematologic recovery (CRi) rate, overall survival (OS), and leukemia free-survival (LFS) across different methylation groups: miR-182 promoter hypomethylation (median value\u2009&lt;\u200920.21%) and hypermethylation (&gt;\u200920.21%) in a retrospective study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The average methylation frequency was markedly higher in 94 AZA\u2009+\u2009VEN-treated elderly or unfit AML patients than that in 20 NCs. However, some AML patients (11.7%) still presented low miR-182 promoter methylation (&lt;\u200910%). The average time to obtain CR\/CRi was shorter in AML patients with miR-182 promoter hypermethylation than AML with hypomethylation. Moreover, the median OS and LFS were longer in AML patients with miR-182 promoter hypermethylation than AML with hypomethylation. Finally, the area under the curve (AUC) for 1-year mortality was 0.831, for 2-year was 0.788, and for 3-year was 0.800.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>AML patients with miR-182 promoter hypermethylation have better outcomes. miR-182 promoter methylation is a predictive biomarker for AZA\u2009+\u2009VEN-treated AML patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13148-025-01823-1","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T18:38:34Z","timestamp":1738780714000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["miR-182 promoter hypermethylation predicts the better outcome of AML patients treated with AZA\u2009+\u2009VEN in a real-world setting"],"prefix":"10.1186","volume":"17","author":[{"given":"Yilan","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bei","family":"Ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zihan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yigang","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liuzhi","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shenmeng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haige","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,5]]},"reference":[{"issue":"5","key":"1823_CR1","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/j.1365-2141.2010.08470.x","volume":"152","author":"DA Pollyea","year":"2011","unstructured":"Pollyea DA, Kohrt HE, Medeiros BC. Acute myeloid leukaemia in the elderly: a review. Br J Haematol. 2011;152(5):524\u201342.","journal-title":"Br J Haematol"},{"issue":"1","key":"1823_CR2","first-page":"60","volume":"109","author":"F Mannelli","year":"2024","unstructured":"Mannelli F, Piccini M, Bencini S, Gianfaldoni G, Peruzzi B, Caporale R, et al. Effect of age and treatment on predictive value of measurable residual disease: implications for clinical management of adult patients with acute myeloid leukemia. Haematologica. 2024;109(1):60\u201371.","journal-title":"Haematologica"},{"issue":"3","key":"1823_CR3","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","volume":"12","author":"ED Lagadinou","year":"2013","unstructured":"Lagadinou ED, Sach A, Callahan K, Rossi RM, Neering SJ, Minhajuddin M, et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 2013;12(3):329\u201341.","journal-title":"Cell Stem Cell"},{"issue":"2","key":"1823_CR4","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202\u20138.","journal-title":"Nat Med"},{"issue":"5","key":"1823_CR5","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1182\/blood.2023023625","volume":"144","author":"F Efficace","year":"2024","unstructured":"Efficace F, Kicinski M, Coens C, Suciu S, van der Velden W, Noppeney R, et al. Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trial. Blood. 2024;144(5):541\u201351.","journal-title":"Blood"},{"issue":"7","key":"1823_CR6","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617\u201329.","journal-title":"N Engl J Med"},{"issue":"1","key":"1823_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7\u201317.","journal-title":"Blood"},{"issue":"2","key":"1823_CR8","doi-asserted-by":"publisher","first-page":"380","DOI":"10.20517\/cdr.2021.125","volume":"5","author":"F Ong","year":"2022","unstructured":"Ong F, Kim K, Konopleva MY. Venetoclax resistance: mechanistic insights and future strategies. Cancer Drug Resist. 2022;5(2):380\u2013400.","journal-title":"Cancer Drug Resist"},{"issue":"4","key":"1823_CR9","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","volume":"10","author":"S Pei","year":"2020","unstructured":"Pei S, Pollyea DA, Gustafson A, Stevens BM, Minhajuddin M, Fu R, et al. Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia. Cancer Discov. 2020;10(4):536\u201351.","journal-title":"Cancer Discov"},{"issue":"7","key":"1823_CR10","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","volume":"9","author":"T Nechiporuk","year":"2019","unstructured":"Nechiporuk T, Kurtz SE, Nikolova O, Liu T, Jones CL, D\u2019Alessandro A, et al. The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells. Cancer Discov. 2019;9(7):910\u201325.","journal-title":"Cancer Discov"},{"issue":"12","key":"1823_CR11","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1038\/s43018-020-00126-z","volume":"1","author":"BM Stevens","year":"2020","unstructured":"Stevens BM, Jones CL, Pollyea DA, Culp-Hill R, D\u2019Alessandro A, Winters A, et al. Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells. Nat Cancer. 2020;1(12):1176\u201387.","journal-title":"Nat Cancer"},{"issue":"1","key":"1823_CR12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41392-021-00870-3","volume":"7","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Riley-Gillis B, Han L, Jia Y, Lodi A, Zhang H, et al. Activation of RAS\/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia. Signal Transduct Target Ther. 2022;7(1):51.","journal-title":"Signal Transduct Target Ther"},{"issue":"13","key":"1823_CR13","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1182\/blood.2020006785","volume":"138","author":"AW Roberts","year":"2021","unstructured":"Roberts AW, Wei AH, Huang DCS. BCL2 and MCL1 inhibitors for hematologic malignancies. Blood. 2021;138(13):1120\u201336.","journal-title":"Blood"},{"issue":"12","key":"1823_CR14","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1158\/2159-8290.CD-18-0140","volume":"8","author":"HE Ramsey","year":"2018","unstructured":"Ramsey HE, Fischer MA, Lee T, Gorska AE, Arrate MP, Fuller L, et al. A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia. Cancer Discov. 2018;8(12):1566\u201381.","journal-title":"Cancer Discov"},{"issue":"1","key":"1823_CR15","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13148-024-01658-2","volume":"16","author":"D Li","year":"2024","unstructured":"Li D, Yuan Y, Meng C, Lin Z, Zhao M, Shi L, et al. Low expression of miR-182 caused by DNA hypermethylation accelerates acute lymphocyte leukemia development by targeting PBX3 and BCL2: miR-182 promoter methylation is a predictive marker for hypomethylation agents + BCL2 inhibitor venetoclax. Clin Epigenetics. 2024;16(1):48.","journal-title":"Clin Epigenetics"},{"issue":"1","key":"1823_CR16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.7150\/thno.77404","volume":"13","author":"S Ye","year":"2023","unstructured":"Ye S, Xiong F, He X, Yuan Y, Li D, Ye D, et al. DNA hypermethylation-induced miR-182 silence targets BCL2 and HOXA9 to facilitate the self-renewal of leukemia stem cell, accelerate acute myeloid leukemia progression, and determine the sensitivity of BCL2 inhibitor venetoclax. Theranostics. 2023;13(1):77\u201394.","journal-title":"Theranostics"},{"issue":"20","key":"1823_CR17","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u2013405.","journal-title":"Blood"},{"issue":"4","key":"1823_CR18","doi-asserted-by":"publisher","first-page":"620","DOI":"10.7326\/0003-4819-103-4-620","volume":"103","author":"JM Bennett","year":"1985","unstructured":"Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103(4):620\u20135.","journal-title":"Ann Intern Med"},{"issue":"1","key":"1823_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/ijlh.13135","volume":"42","author":"D Narayanan","year":"2020","unstructured":"Narayanan D, Weinberg OK. How I investigate acute myeloid leukemia. Int J Lab Hematol. 2020;42(1):3\u201315.","journal-title":"Int J Lab Hematol"},{"key":"1823_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2023.115759","volume":"216","author":"JL Carter","year":"2023","unstructured":"Carter JL, Su Y, Qiao X, Zhao J, Wang G, Howard M, et al. Acquired resistance to venetoclax plus azacitidine in acute myeloid leukemia: in vitro models and mechanisms. Biochem Pharmacol. 2023;216: 115759.","journal-title":"Biochem Pharmacol"},{"issue":"8","key":"1823_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2021.119047","volume":"1868","author":"G Prado","year":"2021","unstructured":"Prado G, Kaestner CL, Licht JD, Bennett RL. Targeting epigenetic mechanisms to overcome venetoclax resistance. Biochim Biophys Acta Mol Cell Res. 2021;1868(8): 119047.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"issue":"20","key":"1823_CR22","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1182\/blood.2021014304","volume":"140","author":"D Thomalla","year":"2022","unstructured":"Thomalla D, Beckmann L, Grimm C, Oliverio M, Meder L, Herling CD, et al. Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies. Blood. 2022;140(20):2113\u201326.","journal-title":"Blood"},{"issue":"20","key":"1823_CR23","doi-asserted-by":"publisher","first-page":"5297","DOI":"10.1182\/bloodadvances.2024013685","volume":"8","author":"FW Hoff","year":"2024","unstructured":"Hoff FW, Blum W, Huang Y, Welkie RL, Swords R, Traer E, et al. Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy. Blood Adv. 2024;8(20):5297\u2013305.","journal-title":"Blood Adv"},{"key":"1823_CR24","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/ijms25126356","volume":"25","author":"O Bruserud","year":"2024","unstructured":"Bruserud O, Selheim F, Hernandez-Valladares M, Reikvam H. Monocytic differentiation in acute myeloid leukemia cells: diagnostic criteria, biological heterogeneity, mitochondrial metabolism, resistance to and induction by targeted therapies. Int J Mol Sci. 2024;25:12.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1823_CR25","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s00277-020-03911-z","volume":"99","author":"YW Wang","year":"2020","unstructured":"Wang YW, Tsai CH, Lin CC, Tien FM, Chen YW, Lin HY, et al. Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax. Ann Hematol. 2020;99(3):501\u201311.","journal-title":"Ann Hematol"},{"issue":"1","key":"1823_CR26","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13148-023-01458-0","volume":"15","author":"S He","year":"2023","unstructured":"He S, Li Y, Shi X, Wang L, Cai D, Zhou J, et al. DNA methylation landscape reveals LIN7A as a decitabine-responsive marker in patients with t(8;21) acute myeloid leukemia. Clin Epigenetics. 2023;15(1):37.","journal-title":"Clin Epigenetics"},{"issue":"8","key":"1823_CR27","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/s43018-020-0103-x","volume":"1","author":"H Zhang","year":"2020","unstructured":"Zhang H, Nakauchi Y, Kohnke T, Stafford M, Bottomly D, Thomas R, et al. Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia. Nat Cancer. 2020;1(8):826\u201339.","journal-title":"Nat Cancer"},{"issue":"21","key":"1823_CR28","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1182\/blood.2024024944","volume":"144","author":"H Dohner","year":"2024","unstructured":"Dohner H, Pratz KW, DiNardo CD, Wei AH, Jonas BA, Pullarkat VA, et al. Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine. Blood. 2024;144(21):2211\u201322.","journal-title":"Blood"},{"issue":"6","key":"1823_CR29","doi-asserted-by":"publisher","first-page":"666","DOI":"10.4149\/neo_2013_085","volume":"60","author":"SV Mehta","year":"2013","unstructured":"Mehta SV, Shukla SN, Vora HH. Overexpression of Bcl2 protein predicts chemoresistance in acute myeloid leukemia: its correlation with FLT3. Neoplasma. 2013;60(6):666\u201375.","journal-title":"Neoplasma"},{"issue":"11","key":"1823_CR30","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1182\/blood.V81.11.3091.3091","volume":"81","author":"L Campos","year":"1993","unstructured":"Campos L, Rouault JP, Sabido O, Oriol P, Roubi N, Vasselon C, et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood. 1993;81(11):3091\u20136.","journal-title":"Blood"},{"issue":"3","key":"1823_CR31","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","volume":"4","author":"R Pan","year":"2014","unstructured":"Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2014;4(3):362\u201375.","journal-title":"Cancer Discov"},{"issue":"20","key":"1823_CR32","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1182\/blood.2022017341","volume":"140","author":"A Condoluci","year":"2022","unstructured":"Condoluci A, Rossi D. Mechanisms of resistance to venetoclax. Blood. 2022;140(20):2094\u20136.","journal-title":"Blood"},{"issue":"13","key":"1823_CR33","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1182\/blood.2021011094","volume":"141","author":"H Kuusanmaki","year":"2023","unstructured":"Kuusanmaki H, Dufva O, Vaha-Koskela M, Leppa AM, Huuhtanen J, Vanttinen I, et al. Erythroid\/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia. Blood. 2023;141(13):1610\u201325.","journal-title":"Blood"},{"issue":"11","key":"1823_CR34","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1038\/leu.2017.82","volume":"31","author":"M Abraham","year":"2017","unstructured":"Abraham M, Klein S, Bulvik B, Wald H, Weiss ID, Olam D, et al. The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a\/16-1 expression. Leukemia. 2017;31(11):2336\u201346.","journal-title":"Leukemia"},{"issue":"1","key":"1823_CR35","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1182\/blood.2020009676","volume":"138","author":"M Feng","year":"2021","unstructured":"Feng M, Xie X, Han G, Zhang T, Li Y, Li Y, et al. YBX1 is required for maintaining myeloid leukemia cell survival by regulating BCL2 stability in an m6A-dependent manner. Blood. 2021;138(1):71\u201385.","journal-title":"Blood"},{"issue":"1","key":"1823_CR36","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1136\/annrheumdis-2018-213970","volume":"78","author":"H Zhu","year":"2019","unstructured":"Zhu H, Wu LF, Mo XB, Lu X, Tang H, Zhu XW, et al. Rheumatoid arthritis-associated DNA methylation sites in peripheral blood mononuclear cells. Ann Rheum Dis. 2019;78(1):36\u201342.","journal-title":"Ann Rheum Dis"},{"issue":"23","key":"1823_CR37","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1182\/blood.2023020855","volume":"142","author":"S Fleming","year":"2023","unstructured":"Fleming S, Tsai XC, Morris R, Hou HA, Wei AH. TP53 status and impact on AML prognosis within the ELN 2022 risk classification. Blood. 2023;142(23):2029\u201333.","journal-title":"Blood"},{"issue":"2","key":"1823_CR38","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1182\/blood.2022016946","volume":"141","author":"EM Stein","year":"2023","unstructured":"Stein EM. IDH2 inhibition in AML. Blood. 2023;141(2):124\u20135.","journal-title":"Blood"},{"issue":"16","key":"1823_CR39","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1182\/blood-2013-03-491571","volume":"122","author":"A Chaturvedi","year":"2013","unstructured":"Chaturvedi A, Araujo Cruz MM, Jyotsana N, Sharma A, Yun H, Gorlich K, et al. Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Blood. 2013;122(16):2877\u201387.","journal-title":"Blood"},{"issue":"25","key":"1823_CR40","doi-asserted-by":"publisher","first-page":"5486","DOI":"10.1182\/blood-2010-02-267955","volume":"116","author":"S Schnittger","year":"2010","unstructured":"Schnittger S, Haferlach C, Ulke M, Alpermann T, Kern W, Haferlach T. IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. Blood. 2010;116(25):5486\u201396.","journal-title":"Blood"},{"issue":"12","key":"1823_CR41","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.1182\/blood-2004-04-1630","volume":"104","author":"KW Zhao","year":"2004","unstructured":"Zhao KW, Li X, Zhao Q, Huang Y, Li D, Peng ZG, et al. Protein kinase Cdelta mediates retinoic acid and phorbol myristate acetate-induced phospholipid scramblase 1 gene expression: its role in leukemic cell differentiation. Blood. 2004;104(12):3731\u20138.","journal-title":"Blood"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-025-01823-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13148-025-01823-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-025-01823-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T23:00:44Z","timestamp":1738796444000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalepigeneticsjournal.biomedcentral.com\/articles\/10.1186\/s13148-025-01823-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,5]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1823"],"URL":"https:\/\/doi.org\/10.1186\/s13148-025-01823-1","relation":{},"ISSN":["1868-7083"],"issn-type":[{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,5]]},"assertion":[{"value":"1 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in our studies involving human participants followed the ethical standards of the Ethics Committee of the First Affiliated Hospital of Wenzhou Medical University. Informed consent for participation was signed by all patients. Animal procedures and care were conducted according to institutional guidelines and followed national and international laws and policies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}